ABSTRACT Gemcitabine is a widely used drug in the treatment of diverse malignancies and its use has been approved by the US Food and Drug Administration. This drug has been associated with a rare adverse event, the Hemolytic Uremic Syndrome (HUS), characterized by acute kidney injury, microangiopathic hemolytic anemia, and...
Using chemotherapy against metastatic pancreatic neuroendocrine neoplasm: how aggressively do we treat it? Real world data from a Brazilian Cancer Center
ABSTRACT Introduction: Pancreatic neuroendocrine neoplasms (pNEN) have poor prognosis. Available treatment options are limited. We aimed to evaluate the clinical characteristics and outcomes in patients with pNEN undergoing systemic chemotherapy. Methods: Retrospective study of patients with metastatic pNEN diagnosed between January 2000 and April 2018 in A.C. Camargo Cancer Center. We evaluated...
ABSTRACT NUT carcinoma (midline testicular carcinoma nuclear protein) is a relatively new, rare, aggressive and underdiagnosed entity. Its sites of involvement are medial structures of the head and neck and mediastinum, but other sites may be affected, and even in so-called common structures, the clinical course may impress. The objective...
ABSTRACT In the last decade, important advances have been made in the treatment of metastatic prostate cancer, resulting in a better understanding of the biology underlying the disease, and in the approval of several therapeutic agents such as immunotherapy, new generation antiandrogens, cytotoxic chemotherapies, and radiopharmaceuticals. All these recent advances...
